Back to Search
Start Over
Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children
- Source :
- Antimicrobial Agents and Chemotherapy. 62
- Publication Year :
- 2018
- Publisher :
- American Society for Microbiology, 2018.
-
Abstract
- Trimethoprim (TMP)-sulfamethoxazole (SMX) is used to treat various types of infections, including community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) and Pneumocystis jirovecii infections in children. Pharmacokinetic (PK) data for infants and children are limited, and the optimal dosing is not known. We performed a multicenter, prospective PK study of TMP-SMX in infants and children. Separate population PK models were developed for TMP and SMX administered by the enteral route using nonlinear mixed-effects modeling. Optimal dosing was determined on the basis of the matching adult TMP exposure and attainment of the surrogate pharmacodynamic (PD) target for efficacy, a free TMP concentration above the MIC over 50% of the dosing interval. Data for a total of 153 subjects (240 samples for PK analysis) with a median postnatal age of 8 years (range, 0.1 to 20 years) contributed to the analysis for both drugs. A one-compartment model with first-order absorption and elimination characterized the TMP and SMX PK data well. Weight was included in the base model for clearance (CL/ F ) and volume of distribution ( V / F ). Both TMP and SMX CL/ F increased with age. In addition, TMP and SMX CL/ F were inversely related to the serum creatinine and albumin concentrations, respectively. The exposure achieved in children after oral administration of TMP-SMX at 8/40 mg/kg of body weight/day divided into administration every 12 h matched the exposure achieved in adults after administration of TMP-SMX at 320/1,600 mg/day divided into administration every 12 h and achieved the PD target for bacteria with an MIC of 0.5 mg/liter in >90% of infants and children. The exposure achieved in children after oral administration of TMP-SMX at 12/60 and 15/75 mg/kg/day divided into administration every 12 h matched the exposure achieved in adults after administration of TMP-SMX at 640/3,200 mg/day divided into administration every 12 h in subjects 6 to
- Subjects :
- Adult
Male
Methicillin-Resistant Staphylococcus aureus
0301 basic medicine
medicine.medical_specialty
Adolescent
030106 microbiology
Population
Clinical Therapeutics
urologic and male genital diseases
Enteral administration
Gastroenterology
Young Adult
03 medical and health sciences
Pharmacokinetics
Oral administration
Internal medicine
Trimethoprim, Sulfamethoxazole Drug Combination
medicine
Humans
Pharmacology (medical)
Prospective Studies
Child
education
Pharmacology
Volume of distribution
education.field_of_study
business.industry
Infant, Newborn
Infant
Liter
Staphylococcal Infections
bacterial infections and mycoses
Trimethoprim
female genital diseases and pregnancy complications
Anti-Bacterial Agents
Infectious Diseases
Child, Preschool
Pharmacodynamics
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 10986596 and 00664804
- Volume :
- 62
- Database :
- OpenAIRE
- Journal :
- Antimicrobial Agents and Chemotherapy
- Accession number :
- edsair.doi.dedup.....852b9bec0565aa27465e740415e34be0
- Full Text :
- https://doi.org/10.1128/aac.01813-17